Clinical efficacy of reversible and selective inhibitors of monoamine oxidase A in major depression.
This article reviews efficacy studies of the reversible selective inhibitor of monoamine oxidase A (MAO-A) moclobemide, which has now received extensive evaluation. Placebo-controlled trials have shown it clearly to be effective. In comparisons with tricyclic and similar antidepressants and with serotonin reuptake inhibitors, it has been found of equal efficacy to these standard drugs. Because of previous suggestions that older MAO inhibitors are particularly effective in depressions characterized as atypical, the effects in subtypes are of particular interest. The evidence indicates that moclobemide is effective in typical severe depression with melancholia rather than being limited to less typical subtypes.
Paykel
E S
ES
Department of Psychiatry, University of Cambridge, Addenbrooke's Hospital, United Kingdom.
D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000494:pharmacology / Q000627:therapeutic use; D001549:Benzamides / Q000494:pharmacology* / Q000627:therapeutic use*; D003866:Depressive Disorder / Q000188:drug therapy*; D006801:Humans; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D012720:Severity of Illness Index
D000929:Antidepressive Agents, Tricyclic; D001549:Benzamides; D020912:Moclobemide; D008996:Monoamine Oxidase Inhibitors; D010919:Placebos; D017367:Selective Serotonin Reuptake Inhibitors